

Walter H Gotlieb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/587500/publications.pdf>

Version: 2024-02-01

135
papers

4,149
citations

136950

32
h-index

133252

59
g-index

137
all docs

137
docs citations

137
times ranked

5295
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of digital patient education in maternal health: A systematic review. <i>Patient Education and Counseling</i> , 2022, 105, 586-593.	2.2	13
2	Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for gynaecological cancer survivors suffering from dyspareunia: a prospective interventional study. <i>Physiotherapy</i> , 2022, 114, 54-62.	0.4	5
3	Mandate to evaluate robotic surgery implementation: a 12-year retrospective analysis of impact and future implications. <i>Journal of Robotic Surgery</i> , 2022, 16, 783-788.	1.8	2
4	Lifetime caffeine intake and the risk of epithelial ovarian cancer. <i>Cancer Epidemiology</i> , 2022, 76, 102058.	1.9	2
5	Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: Results from a one-year follow-up mixed-method study. <i>PLoS ONE</i> , 2022, 17, e0262844.	2.5	13
6	Four protective maneuvers in minimal invasive surgery of endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003324.	2.5	0
7	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. <i>Gynecologic Oncology</i> , 2022, 165, 201-214.	1.4	18
8	Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. <i>NAR Cancer</i> , 2022, 4, zcac013.	3.1	5
9	Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 875-881.	2.5	3
10	Predicting recurrence and recurrence-free survival in high-grade endometrial cancer using machine learning. <i>Journal of Surgical Oncology</i> , 2022, 126, 1096-1103.	1.7	1
11	Dual staining for p16/Ki67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertain Intraepithelial Neoplasia by Immunostain Testing study. <i>International Journal of Cancer</i> , 2021, 148, 492-501.	5.1	11
12	Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 453-458.	2.8	5
13	Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 947-956.	0.6	23
14	Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. <i>International Journal of Cancer</i> , 2021, 148, 2304-2312.	5.1	4
15	Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 2409.	3.3	5
16	Characterizing Pelvic Floor Muscle Function and Morphometry in Survivors of Gynecological Cancer Who Have Dyspareunia: A Comparative Cross-Sectional Study. <i>Physical Therapy</i> , 2021, 101, .	2.4	14
17	Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema. <i>Current Oncology</i> , 2021, 28, 455-470.	2.2	3
18	A Prospective Single-Arm Study Evaluating the Effects of a Multimodal Physical Therapy Intervention on Psychosexual Outcomes in Women With Dyspareunia After Gynecologic Cancer. <i>Journal of Sexual Medicine</i> , 2021, 18, 946-954.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Pathophysiological and anatomical basis of lymphatic transit of cancer cells and role of the lymphatic system: a review of published literature. <i>Chinese Clinical Oncology</i> , 2021, 10, 14-14.	1.2	2
20	Sentinel Lymph Node Sampling as an Alternative to Lymphadenectomy in Patients With Endometrial Cancer and Obesity. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1136-1144.e1.	0.7	8
21	Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 367.e1-367.e39.	1.3	39
22	Development of a Digital Patient Education Tool for Patients With Cancer During the COVID-19 Pandemic. <i>JMIR Cancer</i> , 2021, 7, e23637.	2.4	11
23	Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695404.	2.8	10
24	Perceptions of BELONG as a supportive eâ€platform used by women with gynecologic cancers. <i>Psycho-Oncology</i> , 2021, , .	2.3	2
25	Surgical Technique for Sentinel Lymph Node Sampling in Presumed Early-stage Ovarian Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1446.	0.6	1
26	Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: A pilot project. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100842.	0.6	0
27	Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes. <i>Gynecologic Oncology</i> , 2021, 162, 256-261.	1.4	5
28	SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca ²⁺ flux to mitochondria. <i>Nature Communications</i> , 2021, 12, 5404.	12.8	20
29	Surgical technique for sentinel lymph node sampling in endometrial cancer using the articulated HOOK monopolar instrument. <i>International Journal of Gynecological Cancer</i> , 2021, , ijgc-2021-002840.	2.5	0
30	Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents. <i>Frontiers in Oncology</i> , 2021, 11, 745981.	2.8	3
31	Lifetime recreational moderateâ€toâ€vigorous physical activity and ovarian cancer risk: A caseâ€control study. <i>International Journal of Cancer</i> , 2020, 146, 1800-1809.	5.1	3
32	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. <i>Gynecologic Oncology</i> , 2020, 156, 377-386.	1.4	14
33	Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study. <i>Gynecologic Oncology</i> , 2020, 159, 778-784.	1.4	25
34	Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1 and BRCA2 mutation carriers. <i>Seminars in Cancer Biology</i> , 2020, 77, 110-126.	9.6	16
35	Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2020, 42, 1339-1345.	0.7	5
36	The added value of sentinel node mapping in endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 158, 84-91.	1.4	21

#	ARTICLE	IF	CITATIONS
37	<i>SMARCB1</i> loss induces druggable cyclin <i>D1</i> deficiency via upregulation of <i>MIR17HG</i> in atypical teratoid rhabdoid tumors. <i>Journal of Pathology</i> , 2020, 252, 77-87.	4.5	11
38	Genome-wide DNA methylation profiling identifies two novel genes in cervical neoplasia. <i>International Journal of Cancer</i> , 2020, 147, 1264-1274.	5.1	15
39	CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 933-940.	2.8	19
40	The shifting trends towards a robotically-assisted surgical interface: Clinical and financial implications. <i>Health Policy and Technology</i> , 2020, 9, 157-165.	2.5	12
41	The impact of wait times on oncological outcome in high-risk patients with endometrial cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 306-314.	1.7	3
42	Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1436-1446.	2.5	1
43	Risk factors for lymph nodes involvement in obese women with endometrial carcinomas. <i>Gynecologic Oncology</i> , 2019, 155, 27-33.	1.4	13
44	Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. <i>Molecular Cancer Research</i> , 2019, 17, 2422-2431.	3.4	3
45	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. <i>Nature Communications</i> , 2019, 10, 558.	12.8	76
46	The effect of rural vs. urban setting on the management and outcomes of surgery for endometrial cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2019, 48, 745-749.	1.3	5
47	Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1134-1140.	2.5	23
48	Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 987-995.	2.5	25
49	Immunotherapy of gynecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 60, 97-110.	2.8	14
50	Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2019, 41, 450-458.	0.7	26
51	A three-pronged approach to evaluating robotic surgery. <i>Gynecology and Pelvic Medicine</i> , 2019, 2, 15-15.	0.1	1
52	Evaluating postoperative pain and satisfaction among women treated by robotic surgery for gynecologic cancer. <i>Gynecology and Pelvic Medicine</i> , 2019, 2, 6-6.	0.1	2
53	Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1341-1347.	2.5	27
54	Targeted sequencing of histologically defined serous endometrial cancer reflects prognosis and correlates with preoperative biopsy. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100521.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green) Tj ETQq1 1 0.784314 rgBT /Overbo assignment. International Journal of Gynecological Cancer, 2019, 29, 1121-1125.	2.5	11
56	Robotic Radical Hysterectomy for Cervical Cancer: A Population-Based Study of Adoption and Immediate Postoperative Outcomes in the United States. Journal of Minimally Invasive Gynecology, 2019, 26, 551-557.	0.6	21
57	Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer, 2019, 19, 44.	2.6	11
58	Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. Gynecologic Oncology, 2018, 149, 491-497.	1.4	14
59	Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer. Gynecologic Oncology, 2018, 148, 553-558.	1.4	15
60	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
61	Risk of Thromboembolic Disease With Cost Estimates in Patients Undergoing Robotic Assisted Surgery for Endometrial Cancer and Review of the Literature. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1571-1579.	0.7	13
62	Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study. Lancet Oncology, The, 2018, 19, 1569-1578.	10.7	39
63	Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors. Gynecologic Oncology Reports, 2018, 24, 43-47.	0.6	6
64	Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Obstetrics and Gynecology, 2018, 70, 194-214.	1.0	27
65	Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes and Control, 2017, 28, 393-403.	1.8	30
66	Defining care trajectories: The example of endometrial cancer. Journal of Cancer Policy, 2017, 12, 21-27.	1.4	3
67	Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecologic Oncology, 2017, 144, 503-509.	1.4	41
68	Outside the operating room: How a robotics program changed resource utilization on the inpatient Ward. Gynecologic Oncology, 2017, 145, 102-107.	1.4	4
69	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	3.4	87
70	Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecologic Oncology, 2017, 146, 405-415.	1.4	298
71	Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Preventive Medicine, 2017, 98, 15-20.	3.4	34
72	Does hormonal therapy for fertility preservation affect the survival of young women with earlyâ€stage endometrial cancer?. Cancer, 2017, 123, 1545-1554.	4.1	39

#	ARTICLE	IF	CITATIONS
73	Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 474-479.	1.4	25
74	Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 493-506.	329.8	58
75	Unexpected locations of sentinel lymph nodes in endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 18-23.	1.4	33
76	Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 30-35.	1.4	11
77	Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 737-743.	2.3	21
78	Minimizing pain medication use and its associated costs following robotic surgery. <i>Gynecologic Oncology</i> , 2017, 144, 187-192.	1.4	13
79	Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. <i>BMC Cancer</i> , 2017, 17, 638.	2.6	82
80	Benefits of Minimal Access Surgery in Elderly Patients with Pelvic Cancer. <i>Cancers</i> , 2016, 8, 12.	3.7	12
81	Ovarian cancer screening: UKCTOCS trial. <i>Lancet, The</i> , 2016, 387, 2602-2603.	13.7	4
82	Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia. <i>Oncology Letters</i> , 2016, 12, 3135-3142.	1.8	10
83	Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1213-1221.	2.5	29
84	Hysterectomy for Uterine Cancer in the Elderly: A Comparison Between Laparoscopic and Robot-Assisted Techniques. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1222-1227.	2.5	9
85	Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. <i>BMC Medicine</i> , 2015, 13, 217.	5.5	17
86	Outcome of Robotic Surgery for Endometrial Cancer as a Function of Patient Age. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 637-644.	2.5	30
87	Current Role of Sentinel Lymph Node Mapping in Endometrial Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2015, 13, 1.	0.3	0
88	Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 776-780.	2.8	8
89	Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. <i>BMC Cancer</i> , 2015, 15, 817.	2.6	25
90	Virtual reality robotic surgery simulation curriculum to teach robotic suturing: a randomized controlled trial. <i>Journal of Robotic Surgery</i> , 2015, 9, 179-186.	1.8	36

#	ARTICLE	IF	CITATIONS
91	Role of Laparoscopic and Robotic Surgery in Endometrial Cancer: The Inevitable Evolution. , 2015, , 231-247.		0
92	Sentinel lymph node procedure in endometrial cancer: A systematic review and proposal for standardization of future research. Gynecologic Oncology, 2015, 138, 478-485.	1.4	131
93	Laparoscopic and robot-assisted hysterectomy for uterine cancer: a comparison of costs and complications. American Journal of Obstetrics and Gynecology, 2015, 213, 665.e1-665.e7.	1.3	32
94	Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. Anticancer Research, 2015, 35, 2893-900.	1.1	1
95	Akt-Activated Endothelium Constitutes the Niche for Residual Disease and Resistance to Bevacizumab in Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3123-3136.	4.1	29
96	Impact of robotics on the outcome of elderly patients with endometrial cancer. Gynecologic Oncology, 2014, 133, 556-562.	1.4	70
97	Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecologic Oncology, 2014, 134, 607-614.	1.4	97
98	Virtual Reality Surgical Simulators- A Prerequisite for Robotic Surgery. Indian Journal of Surgical Oncology, 2014, 5, 125-127.	0.7	19
99	Prospective Quality of Life Outcomes Following Robotic Surgery in Gynecologic Oncology. Gynecologic Oncology, 2014, 134, 144-149.	1.4	17
100	Health-Related Quality of Life Following Robotic Surgery: A Pilot Study. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 1071-1078.	0.7	9
101	Fertility preserving treatments for endometrial cancer: The unanswered questions. Gynecologic Oncology, 2013, 129, 1-2.	1.4	15
102	Vaginal Vault Dehiscence After Robotic Hysterectomy for Gynecologic Cancers: Search for Risk Factors and Literature Review. International Journal of Gynecological Cancer, 2013, 23, 943-950.	2.5	40
103	Brain Metastases in Women With Epithelial Ovarian Cancer: Multimodal Treatment Including Surgery or Gamma-Knife Radiation Is Associated With Prolonged Survival. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 816-822.	0.7	19
104	Controversies in the Treatment of Early Stage Endometrial Carcinoma. Obstetrics and Gynecology International, 2012, 2012, 1-8.	1.3	28
105	Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery. Obstetrics and Gynecology, 2012, 119, 717-724.	2.4	112
106	Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 567-574.	0.7	14
107	Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology, The, 2012, 13, 154-162.	10.7	141
108	Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study. Gynecologic Oncology, 2012, 127, 332-337.	1.4	77

#	ARTICLE	IF	CITATIONS
109	Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 694-699.	2.1	80
110	Relationship Between Body Mass Index and Robotic Surgery Outcomes of Women Diagnosed With Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 722-729.	2.5	44
111	Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. <i>Gynecologic Oncology</i> , 2011, 121, 492-498.	1.4	113
112	Anesthesia considerations for robotic surgery in gynecologic oncology. <i>Journal of Robotic Surgery</i> , 2011, 5, 235-239.	1.8	16
113	Laparoscopic Surgery for Endometrial Cancer: A Review. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010, 32, 570-579.	0.7	19
114	Robotic radical hysterectomy: comparison of outcomes and cost. <i>Journal of Robotic Surgery</i> , 2010, 4, 211-216.	1.8	20
115	Technical modifications in the robotic-assisted surgical approach for gynaecologic operations. <i>Journal of Robotic Surgery</i> , 2010, 4, 253-257.	1.8	12
116	Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-11.	1.3	56
117	Outcome and quality of life in a prospective cohort of the first 100 robotic surgeries for endometrial cancer, with focus on elderly patients. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1367-73.	2.5	38
118	Intraperitoneal Chemotherapy: Why the Fuzz?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, S14-S16.	2.5	2
119	BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. <i>Gynecologic Oncology</i> , 2009, 115, 193-198.	1.4	28
120	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 110, 246-250.	1.4	249
121	Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 389-396.	1.4	66
122	Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 780-783.	1.4	68
123	Outcome of Fertility-Sparing Treatment With Progestins in Young Patients With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2004, 103, 998.	2.4	1
124	The assessment and surgical management of early-stage vulvar cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2003, 17, 557-569.	2.8	14
125	Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. <i>Obstetrics and Gynecology</i> , 2003, 102, 718-725.	2.4	146
126	Infertility treatment after conservative management of borderline ovarian tumors. <i>Cancer</i> , 2001, 92, 320-325.	4.1	67

#	ARTICLE	IF	CITATIONS
127	Prophylactic oophorectomy: Clinical considerations. <i>Journal of Surgical Oncology</i> , 2000, 19, 20-27.	1.4	13
128	Expression of topoisomerase II and Ki-67 in cervical carcinoma: a clinicopathological study using immunohistochemistry. <i>Apmis</i> , 2000, 108, 209-215.	2.0	24
129	p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 849-854.	2.3	11
130	Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 501-508.	3.3	20
131	Macrophage infiltration and angiogenesis in cervical squamous cell carcinoma: clinicopathologic correlation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1999, 78, 240-244.	2.8	19
132	High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 799-808.	3.3	162
133	Intraperitoneal Pressures and Clinical Parameters of Total Paracentesis for Palliation of Symptomatic Ascites in Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 71, 381-385.	1.4	68
134	Borderline tumors of the ovary. <i>Cancer</i> , 1998, 82, 141-146.	4.1	157
135	Borderline tumors of the ovary. <i>Cancer</i> , 1998, 82, 141-146.	4.1	3